glp 1 for crohn's disease Recommendations the safe and effective use of GLP-1 RA in people GLP-1 IBD obesity "inflammatory bowel

Significance statement ![Figure][1] ### Competing Interest Statement The authors have declared no competing interest

The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity

You get full faster

Study outcomes included the number needed to treat (NNT) to prevent one case of clinical events, healthcare costs, and cost per case of event prevented

During a presentation at the American Association of Clinical Endocrinology Annual Scientific and Clinical Conference, Justin Do, DO, an endocrinology fellow at Loma Linda University Medical Center in

THIS YEAR, at the American College of Rheumatology (ACR) Convergence 2025, a dedicated session explored whether glucagon-like peptide-1...